KSQ Therapeutics, a privately-held US biotech developing therapies to treat cancer and autoimmune diseases using its CRISPRomics platform, has announced a deal with Ono Pharmaceutical (TYO: 4528).
The Japanese drugmaker has acquired multiple research-stage DNA damage response programs identified using KSQ’s platform.
"We expect that the programs acquired from KSQ will lead to the creation of innovative medicines"All of the programs are novel and have the potential to become first-in-class therapies, according to KSQ.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze